HealthCap
HealthCap
  • About
    • Our Story
    • Strategy
    • ESG Policy
    • Partners
    • Team
    • Special Advisors
  • 1996 – 2021
  • Investments
    • Portfolio Companies
    • Approved Products
  • News
    • Portfolio Companies
    • HealthCap
  • Contact & Legal
    • Contact Us
    • Privacy Policy
    • Cookie Policy
  • LinkedIn
  • Wikipedia
HealthCap

HealthCap is a family of venture capital funds investing globally in life sciences. With more than EUR 1.2 billion raised since the start in 1996, HealthCap is one of the largest specialized providers of venture capital within life sciences in Europe.

Read more

Portfolio Companies News

  • January 30, 2023
    Aprea Therapeutics Appoints John Ha...

    DOYLESTOWN, Pa., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced the appointmen... read more

  • January 23, 2023
    Priothera announces first patients ...

    Mocravimod is the only S1PR modulator being developed to treat blood cancers and improve CAR-T therapy  Phase 1b/2a data has shown mocravimod is safe and well tolerated Dublin, Ireland – January 23, 2023 – Priothera, a late-clinical stage biotechnology company pioneering th... read more

  • January 11, 2023
    Aprea Therapeutics Announces Dosing...

    DOYLESTOWN, Pa., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that the first pat... read more

  • January 11, 2023
    Oncopeptides appoints Holger Lembre...

    STOCKHOLM — January 11, 2023 — Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the Company has appointed Holger Lembrer as Chief Financial Officer, CFO. Prior... read more

  • January 10, 2023
    Hemab Therapeutics Announces First ...

    Bispecific antibody HMB-001 positioned as the first prophylactic treatment for rare bleeding disorders CEO Benny Sorensen, MD, PhD, delivered the update during a corporate overview presented at the 41st Annual JP Morgan Healthcare Conference COPENHAGEN, DENMARK AND BOSTON, MASS., US... read more

HealthCap Info

  • December 23, 2022
    Q3 2022 General Market Overview
  • October 07, 2021
    HealthCap strengthens senior team
  • November 29, 2021
    HealthCap’s 25th company anniversary!

Facts

  • 126

    Since the start in 1996, HealthCap funds have invested in 126 portfolio companies.

    Read more
  • 46

    46 of the portfolio companies have been taken public on fourteen different markets.

    Read more
  • 31

    31 of the portfolio companies pharmaceutical products have been approved for marketing.

    Read more
  • 12

    Unicorn Factory
    Since the start in 1996, HealthCap has helped build 12 companies with a valuation of USD 1 billion or more.

    Read more

Our story

HealthCap is a European venture capital firm investing exclusively and globally in life sciences. The investment strategy focuses on diseases with high unmet medical needs and breakthrough therapies that have the potential to be transformative...

Read more

Subscribe to news

Venture Capital for Breakthrough Therapies

This site uses cookies. But first we need your consent. More info.

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close